![]() The reader is cautioned not to place undue reliance on any forward-looking information. Important factors that could cause actual results to differ materially from the Company's expectations including the risks detailed from time to time in the Company's public disclosure. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. This news release contains forward-looking statements. Samantha DeLenardo, VP, Communications Email: Mitoulas, Investor Relations Email: Statements Novamind Yaron Conforti, CEO and Director Telephone: +1 (647) 953 9512 For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca. Both Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics and clinical research sites. To learn more about the Palliative Program, visit About Novamind "Psychedelic Palliative Care by Novamind is designed to address this need, bringing together fast-acting medicine, innovative treatment options and therapeutic expertise in a safe, nurturing environment." "Our healthcare system struggles to support the millions of Americans dealing with emotional, spiritual and psychological suffering associated with chronic or serious illness," noted Dr. Thielking leads the Palliative Program's multidisciplinary team of mental health professionals specialized in palliative care and psychedelic-assisted psychotherapy. He also pioneered an ongoing HCI study examining the feasibility of group-administered psilocybin-assisted psychotherapy for cancer patients experiencing depression. Thielking developed ketamine-assisted treatment protocols for cancer patients experiencing depression at the University of Utah Huntsman Cancer Institute (HCI). ![]() This work will build on notable studies from New York University and Johns Hopkins University, which demonstrated psilocybin's significant immediate and sustained improvements in anxiety and depression symptoms in cancer patients. Through Novamind's clinical research division, the Palliative Program will host studies to investigate the use of psychedelic medicine including ketamine and establish the infrastructure for future clinical studies examining psilocybin. "Due to psychedelic medicine's generally low side effect burden and fast-acting nature, it shows promise for patients who are physically ill and might have limited life expectancies." Paul Thielking, Chief Scientific Officer (CSO) of Novamind. ![]() Unfortunately, standard anti-depression and anti-anxiety treatments do not work for everyone, can cause side effects, and can take up to eight weeks to work," explained Dr. "Patients receiving palliative care have higher rates of depression than the general population. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, is pleased to launch Psychedelic Palliative Care by Novamind (the "Palliative Program") at its recently opened clinic and research site in Murray, Utah.Īmong the first-of-its-kind, the Palliative Program combines psychedelic medicine with psychotherapy, workshops, multi-day immersive retreats and group support for palliative care patients and families who are coping with chronic and serious illness. TORONTO, ON / ACCESSWIRE / Octo/ Novamind Inc. ![]() Specialized program to research and scale access to psychedelic medicine opens new doors for patients with chronic and serious illness ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |